Scenarios that move MRK
Merck & Company, Inc. Common Stock (new)
Scenarios that move MRK: 25 analyses, 4 positive, 21 negative.
- · OPKO Health to sell BioReference assets to Labcorp for $722M — ▲ · impact +10 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▼ · impact -27 · confidence medium · horizon quarters
- · RARE's Fayuvi approval triggers second $203 million PRV sale — ▼ · impact -33 · confidence low · horizon weeks
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -12 · confidence low · horizon weeks
- · ◇ What if… Democrats win Michigan Senate race in 2026 — ▼ · impact -48 · confidence medium · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▼ · impact -68 · confidence high · horizon immediate
- · Bavarian Nordic raises 2026 outlook after strong Travel Health results — ▼ · impact -25 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▼ · impact -30 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▼ · impact -27 · confidence medium · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -10 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -35 · confidence medium · horizon quarters
- · ◇ What if… Democrats win Kansas Senate race in 2026 — ▼ · impact -35 · confidence low · horizon quarters
- · ◇ What if… Democrats win South Carolina Senate race in 2026 — ▼ · impact -40 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +16 · confidence medium · horizon weeks
- · United Therapeutics stock rises 12.6% in trading — ▼ · impact -24 · confidence medium · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -19 · confidence low · horizon weeks
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -35 · confidence low · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▼ · impact -34 · confidence medium · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -25 · confidence low · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -30 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +40 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▼ · impact -21 · confidence medium · horizon quarters
- · ◇ What if… Democrats win control of Senate and House after 2026 midterms — ▼ · impact -33 · confidence low · horizon quarters
- · ◇ What if… Democrats win control of the House after 2026 midterm elections — ▼ · impact -20 · confidence low · horizon quarters
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▲ · impact +32 · confidence medium · horizon quarters